A thalidomide–hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes

Experimental Hematology

Volumn 58, Issue , 2018, Pages 35-38

  Lanaro, Carolina ^a   Franco Penteado, Carla F ^a   Silva, Fabio H ^a   Fertrin, Kleber Y ^a   dos Santos, Jean Leandro ^b   Wade, Marlene ^c   Yerigenahally, Shobha ^c   de Melo, Thais R ^b   Chin, Chung Man ^b   Kutlar, Abdullah ^c   Meiler, Steffen E ^c   Costa, Fernando Ferreira ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1,3 DIOXOISOINDOLIN 2 YL)BENZYL NITRATE; ANTIANEMIC AGENT; CXCL1 CHEMOKINE; DEXAMETHASONE; HEMOGLOBIN F; HYDROXYUREA; INTERLEUKIN 1BETA; INTERLEUKIN 6; THALIDOMIDE; UNCLASSIFIED DRUG; CYTOKINE;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EX VIVO STUDY; MALE; MONOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAD MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SICKLE CELL ANEMIA; SYNTHESIS;

ANEMIA, SICKLE CELL; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FETAL HEMOGLOBIN; HYDROXYUREA; INFLAMMATION; MICE; MICE, KNOCKOUT; THALIDOMIDE;

EID: 85036647241     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2017.10.003     Document Type: Article

References (24)

1. Akinsheye, I., Alsultan, A., Solovieff, N., et al. Fetal hemoglobin in sickle cell anemia. Blood 118 (2011), 19–27.
2. Humphries, C., Drug development: a complicated path. Nature 515 (2014), S4–S5.
3. Cokic, V.P., Smith, R.D., Beleslin-Cokic, B.B., et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111 (2003), 231–239.
4. Steinberg, M.H., Lu, Z.H., Barton, F.B., Terrin, M.L., Charache, S., Dover, G.J., Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89 (1997), 1078–1088.
5. Charache, S., Terrin, M.L., Moore, R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995), 1317–1322.
6. Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., Rodgers, G.P., Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110 (2007), 2864–2871.
7. Moutouh-de Parseval, L.A., Verhelle, D., Glezer, E., et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 118 (2008), 248–258.
8. Meiler, S.E., Wade, M., Kutlar, F., et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood 118 (2011), 1109–1112.
9. Dulmovits, B.M., Appiah-Kubi, A.O., Papoin, J., et al. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood 127 (2016), 1481–1492.
10. dos Santos, J.L., Lanaro, C., Lima, L.M., et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. J Med Chem 54 (2011), 5811–5819.
11. Silva, F.H., Karakus, S., Musicki, B., et al. Beneficial effect of the nitric oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment. J Pharmacol Exp Ther 359 (2016), 230–237.
12. Ryan, T.M., Ciavatta, D.J., Townes, T.M., Knockout-transgenic mouse model of sickle cell disease. Science 278 (1997), 873–876.
13. Manwani, D., Frenette, P.S., Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122 (2013), 3892–3898.
14. Shannon, E., Noveck, R., Sandoval, F., Kamath, B., Kearney, M., Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res 150 (2007), 275–280.
15. Shannon, E., Noveck, R., Sandoval, F., Kamath, B., Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 30 (2008), 447–457.
16. Godin, A.M., Araújo, D.P., Menezes, R.R., et al. Activities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema. Pharmacol Biochem Behav 122 (2014), 291–298.
17. Lanaro, C., Franco-Penteado, C.F., Albuqueque, D.M., Saad, S.T.O., Conran, N., Costa, F.F., Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 85 (2009), 235–242.
18. Pitanga, T.N., Oliveira, R.R., Zanette, D.L., et al. Sickle red cells as danger signals on proinflammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell. Cytokine 83 (2016), 75–84.
19. Sarray, S., Saleh, L.R., Lisa Saldanha, F., Al-Habboubi, H.H., Mahdi, N., Almawi, W.Y., Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition. Cytokine 72 (2015), 43–47.
20. Jang, J.E., Hod, E.A., Spitalnik, S.L., Frenette, P.S., CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions. J Clin Invest 121 (2011), 1397–1401.
21. Lopez-Millan, B., Diaz de la Guardia, R.D., Roca-Ho, H., et al. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med, 49, 2017, e290.
22. Navarra, P., Grohmann, U., Nocentini, G., et al. Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo. J Pharmacol Exp Ther 280 (1997), 477–482.
23. Tavakkoli, F., Nahavandi, M., Wyche, M.Q., Perlin, E., Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea. Hematology 9 (2004), 61–64.
24. Laurance, S., Pellay, F.X., Dossou-Yovo, O.P., et al. Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease. Pharmacogenet Genomics 20 (2010), 257–268.